HRA Pharma

HRA Pharma is a Paris-based pharmaceutical company focused on women’s health and endocrinology. It develops and commercializes medicines, devices, and related services, with a portfolio spanning emergency contraception, reproductive health therapies, and endocrine treatments. The company markets products such as emergency contraception options, cervical ripening agents, hormone therapies, and the copper intrauterine device, alongside endocrinology medicines for conditions including adrenal disorders and related diseases. It also markets asthma and Parkinson’s disease therapies in certain markets and provides information services for healthcare providers. HRA Pharma pursues an active development pipeline that includes additional emergency contraception options, uterine fibroid treatments, and exploratory cell-based therapies for muscle regeneration. Distribution is primarily EU-focused, with operations in France, Germany, the United Kingdom, and partnerships for international licensing; the company maintains subsidiaries in Bochum, London, and New York to support its regional activities.